AstraZeneca Buys Boston-Based Startup In Fresh AI Push For Cancer Pipeline

Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio.

Pharmaceutical giant AstraZeneca (AZN) has purchased Boston-based biomedical AI company Modella AI for an undisclosed sum, according to a statement from the startup on Tuesday.

Modella said that the buyout is aimed at expanding the two companies’ existing collaboration for advancing the application of artificial intelligence across the drugmaker’s cancer drug portfolio.

The company added that the acquisition will embed Modella AI’s multi-modal foundation models and AI agents into AstraZeneca’s oncology research and development environment. 

Get updates to this developing story directly on Stocktwits.<